{"id":"favipiravir-hydroxychloroquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Retinopathy (hydroxychloroquine)"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Favipiravir is a nucleoside analog that selectively inhibits viral RNA-dependent RNA polymerase, preventing viral genome replication. Hydroxychloroquine is an immunomodulator that increases endosomal pH, inhibits toll-like receptor signaling, and has direct antiviral activity. The combination aims to suppress both viral replication and excessive inflammatory responses.","oneSentence":"Favipiravir inhibits viral RNA polymerase while hydroxychloroquine modulates immune response and has antiviral properties, together targeting viral replication and host inflammatory pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:18.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (Phase 3 evaluation)"},{"name":"Viral respiratory infections"}]},"trialDetails":[{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT06223984","phase":"PHASE4","title":"Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients","status":"COMPLETED","sponsor":"Konya City Hospital","startDate":"2020-03-30","conditions":"Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients","enrollment":178},{"nctId":"NCT04501783","phase":"PHASE3","title":"Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-05-20","conditions":"COVID-19","enrollment":168},{"nctId":"NCT04387760","phase":"PHASE2","title":"Favipiravir vs Hydroxychloroquine vs Control in COVID -19","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-08-11","conditions":"SARS-CoV 2, COVID-19","enrollment":150},{"nctId":"NCT04303299","phase":"PHASE3","title":"Fight COVID-19 Trial","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-08-19","conditions":"SARS-COV-2 Infections, COVID-19","enrollment":320},{"nctId":"NCT04392973","phase":"NA","title":"FAvipiravir and HydroxyChloroquine Combination Therapy","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2020-05-21","conditions":"COVID19","enrollment":268},{"nctId":"NCT04981379","phase":"PHASE3","title":"Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-11-16","conditions":"Covid19","enrollment":1120},{"nctId":"NCT04932889","phase":"","title":"Musculoskeletal Symptoms in Post Acute Covid-19 Patients","status":"COMPLETED","sponsor":"Eskisehir City Hospital","startDate":"2021-06-11","conditions":"Covid19, Musculoskeletal Abnormalities","enrollment":280},{"nctId":"NCT04411433","phase":"PHASE3","title":"Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"Ministry of Health, Turkey","startDate":"2020-05-08","conditions":"Sars-CoV2, COVID-19","enrollment":1008},{"nctId":"NCT04646109","phase":"PHASE3","title":"Ivermectin for Severe COVID-19 Management","status":"COMPLETED","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2020-05-11","conditions":"COVID-19","enrollment":66},{"nctId":"NCT04542694","phase":"PHASE3","title":"Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-05-21","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04558463","phase":"PHASE3","title":"The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2020-04-16","conditions":"Covid19","enrollment":100},{"nctId":"NCT04349241","phase":"PHASE3","title":"Efficacy and Safety of Favipiravir in Management of COVID-19","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-18","conditions":"Coronavirus Disease (COVID-19)","enrollment":100},{"nctId":"NCT04434248","phase":"PHASE2, PHASE3","title":"An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Chromis LLC","startDate":"2020-04-23","conditions":"COVID-19","enrollment":330},{"nctId":"NCT04376814","phase":"NA","title":"Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19","status":"COMPLETED","sponsor":"Baqiyatallah Medical Sciences University","startDate":"2020-03-29","conditions":"COVID-19, Favipiravir, Kaletra","enrollment":40},{"nctId":"NCT04359615","phase":"PHASE4","title":"Favipiravir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-20","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04333589","phase":"NA","title":"Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2020-04-01","conditions":"COVID-19","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Favicovir Film Tablet + Hydroxychloroquine sulfate"],"phase":"phase_3","status":"active","brandName":"Favipiravir + Hydroxychloroquine","genericName":"Favipiravir + Hydroxychloroquine","companyName":"Health Institutes of Turkey","companyId":"health-institutes-of-turkey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Favipiravir inhibits viral RNA polymerase while hydroxychloroquine modulates immune response and has antiviral properties, together targeting viral replication and host inflammatory pathways. Used for COVID-19 (Phase 3 evaluation), Viral respiratory infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}